Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma
Stopped PI no longer interested in pursuing study.
Conditions
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Interventions
- OTHER: Laboratory Biomarker Analysis
- OTHER: Quality-of-Life Assessment
- DRUG: Simvastatin
Sponsor
Wake Forest University Health Sciences
Collaborators